JPMorgan analyst Eric Joseph reiterated an Overweight rating and $30.00 price target on Nurix (NASDAQ: NRIX).The analyst comments "Nurix reported ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Nurix (NRIX) PT Raised to $23 at RBC CapitalApril 11, 2024 6:28 AM Form 10-Q Nurix Therapeutics, Inc. For: Feb 29April 10, 2024 7:06 AM Form 8-K Nurix Therapeutics, Inc. For: Apr 10April 10, 2024 7:02 AM Nurix Therapeutics, Inc. (NRIX) Tops Q1 EPS by 2cApril 10, 2024 7:01 AM Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate UpdateApril 10, 2024 7:00 AM Nurix Therapeutics (NRIX) Reports First Clinical Evidence of CNS Activity of NX-5948April 9, 2024 1:19 PM Form 8-K Nurix Therapeutics, Inc. For: Apr 09April 9, 2024 1:18 PM Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell MalignanciesApril 9, 2024 1:15 PM Nurix Therapeutics (NRIX) Announces Extension of Strategic Collaboration with Sanofi (SNY) to Develop Novel Targeted Protein Degraders of STAT6April 9, 2024 7:13 AM Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6April 9, 2024 7:00 AM